Cited by 201Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 64 of the 65 references it cites were found in a registry or an index.

Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease

Open access

Britschgi, M., Olin, C. E., Johns, H. T., Takeda-Uchimura, Y., LeMieux, M. C., Rufibach, K., Rajadas, J., Zhang, H., Tomooka, B., Robinson, W. H., Clark, C. M., Fagan, A. M., Galasko, D. R., Holtzman, D. M., Jutel, M., Kaye, J. A., Lemere, C. A., Leszek, J., Li, G., Peskind, E. R., Quinn, J. F., Yesavage, J. A., Ghiso, J. A., Wyss-Coray, T.·2009·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.0904866106PMC PMC2715538

Open this paper in CoChat — free account

Abstract

A number of distinct β-amyloid (Aβ) variants or multimers have been implicated in Alzheimer's disease (AD), and antibodies recognizing such peptides are in clinical trials. Humans have natural Aβ-specific antibodies, but their diversity, abundance, and function in the general population remain largely unknown. Here, we demonstrate with peptide microarrays the presence of natural antibodies against known toxic Aβ and amyloidogenic non-Aβ species in plasma samples and cerebrospinal fluid of AD patients and healthy controls aged 21–89 years. Antibody reactivity was most prominent against oligomeric assemblies of Aβ and pyroglutamate or oxidized residues, and IgGs specific for oligomeric preparations of Aβ1-42 in particular declined with age and advancing AD. Most individuals showed unexpected antibody reactivities against peptides unique to autosomal dominant forms of dementia (mutant Aβ, ABri, ADan) and IgGs isolated from plasma of AD patients or healthy controls protected primary neurons from Aβ toxicity. Aged vervets showed similar patterns of plasma IgG antibodies against amyloid peptides, and after immunization with Aβ the monkeys developed high titers not only against Aβ peptides but also against ABri and ADan peptides. Our findings support the concept of conformation-specific, cross-reactive antibodies that may protect against amyloidogenic toxic peptides. If a therapeutic benefit of Aβ antibodies can be confirmed in AD patients, stimulating the production of such neuroprotective antibodies or passively administering them to the elderly population may provide a preventive measure toward AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1073/pnas.0904866106

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
Retracted
Regularization and Variable Selection Via the Elastic Net
Zou, H., & Hastie, T. (2005) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2005.00503.x · Cited by 20,957
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F. Z., Miled, S. B., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,785
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Java Treeview—extensible visualization of microarray data
Saldanha, A. J. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth349 · Cited by 2,991
Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416

Show all 65 references

Sorted by citations

Items 101–200 of 201

A combination of multiple autoantibodies is associated with the risk of Alzheimer’s disease and cognitive impairment
Shim, S.-M., Koh, Y. H., Kim, J., & Jeon, J. (2022) · Scientific Reports · doi:10.1038/s41598-021-04556-2 · Cited by 18
Profiling the autoantibody repertoire reveals autoantibodies associated with mild cognitive impairment and dementia
Ehtewish, H., Mesleh, A. G., Ponirakis, G., Lennard, K. S., Hamad, H. K. A., Chandran, M., Parray, A., Abdesselem, H., Wijten, P., Decock, J. V., et al. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1256745 · Cited by 20
Linear and conformation specific antibodies in aged beagles after prolonged vaccination with aggregated Abeta
Vasilevko, V., Pop, V., Kim, H. J., Saing, T., Glabe, C. C., Milton, S. C. F., Barrett, E. G., Cotman, C. W., Cribbs, D. H., & Head, E. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.04.014 · Cited by 19
Characterizing Aging, Mild Cognitive Impairment, and Dementia with Blood-Based Biomarkers and Neuropsychology
Kleinschmidt, M., Schoenfeld, R., Göttlich, C., Bittner, D., Metzner, J. E., Leplow, B., & Demuth, H. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-143189 · Cited by 21
Autopolyreactivity Confers a Holistic Role in the Immune System
Avraméas, S. (2016) · Scandinavian Journal of Immunology · doi:10.1111/sji.12414 · Cited by 19
Serum naturally occurring anti-TDP-43 auto-antibodies are increased in amyotrophic lateral sclerosis
Conti, E., Sala, G., Diamanti, S., Casati, M., Lunetta, C., Gerardi, F., Tarlarini, C., Mosca, L., Riva, N., Falzone, Y., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-81599-5 · Cited by 19
¿Existe la enfermedad de Alzheimer en todos los primates? Patología Alzheimer en primates no humanos y sus implicaciones fisiopatológicas (II)
Tolédano, A., Álvarez, M. I., López-Rodríguez, A. B., Toledano‐Díaz, A., & Fernández, C. I. (2011) · Neurología · doi:10.1016/j.nrl.2011.05.004 · Cited by 18
B Lymphocytes in Alzheimer’s Disease—A Comprehensive Review
Plantone, D., Pardini, M., Locci, S., Nobili, F. M., & Stefano, N. D. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220261 · Cited by 19
Antibody Signatures Defined by High-Content Peptide Microarray Analysis
Masch, A., Zerweck, J., Reimer, U., Wenschuh, H., & Schutkowski, M. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-845-4_13 · Cited by 17
Donepezil modulates the endogenous immune response: implications for Alzheimer's disease
Conti, E., Tremolizzo, L., Santarone, M. E., Tironi, M., Radice, I., Zoia, C., Aliprandi, A., Salmaggi, A., Dominici, R., Casati, M., et al. (2016) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2538 · Cited by 17
IgG Conformer's Binding to Amyloidogenic Aggregates
Phay, M., Welzel, A. T., Williams, A. D., McWilliams‐Koeppen, H. P., Blinder, V., O’Malley, T. T., Solomon, A., Walsh, D. M., & O’Nuallain, B. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137344 · Cited by 16
S100A9 Protein Aggregates Boost Hippocampal Glutamate Modifying Monoaminergic Neurochemistry: A Glutamate Antibody Sensitive Outcome on Alzheimer-like Memory Decline
Алексеевна, Г. М., Davydova, T. V., Кудрин, В. С., Wang, C., Narkevich, V. B., Morozova‐Roche, L. A., & Sewell, R. D. E. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00379 · Cited by 17
Beyond the amyloid hypothesis: how current research implicates autoimmunity in Alzheimer’s disease pathogenesis
Chatanaka, M. K., Sohaei, D., Diamandis, E. P., & Prassas, I. (2023) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2023.2187342 · Cited by 15
¿Existe la enfermedad de Alzheimer en todos los primates? Afección de Alzheimer en primates no humanos y sus implicaciones fisiopatológicas (I)
Tolédano, A., Álvarez, M. I., López-Rodríguez, A. B., Toledano‐Díaz, A., & Fernández, C. I. (2011) · Neurología · doi:10.1016/j.nrl.2011.05.008 · Cited by 16
Is Alzheimer disease a failure of mobilizing immune defense? Lessons from cognitively fit oldest-old
Katsel, P., & Haroutunian, V. H. (2019) · Phlebolymphology · doi:10.31887/dcns.2019.21.1/vharoutunian · Cited by 14
Integrated bioinformatics-based identification of diagnostic markers in Alzheimer disease
Chen, D., Zhang, Y., Qiao, R., Kong, X., Zhong, H., Wang, X., Zhu, J., & Li, B. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.988143 · Cited by 17
Potential sources of interference on Abeta immunoassays in biological samples
Vanderstichele, H., Stoops, E., Vanmechelen, E., & Jeromin, A. (2012) · Alzheimer s Research & Therapy · doi:10.1186/alzrt142 · Cited by 15
Carriers of the p.P522R variant in PLCγ2 have a slightly more responsive immune system
Diks, A. M., Teodosio, C., de Mooij, B., Groenland, R. J., Naber, B. A. E., de Laat, I. F., Vloemans, S. A., Rohde, S., de Jonge, M. I., Lorenz, L., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00604-9 · Cited by 14
Intruders or protectors – the multifaceted role of B cells in CNS disorders
Aspden, J. W., Murphy, M. A., Kashlan, R. D., Xiong, Y., Poznansky, M. C., & Sîrbulescu, R. F. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1329823 · Cited by 16
A Special Connection between γδ T Cells and Natural Antibodies?
Born, W. K., Huang, Y., Zeng, W., Torres, R. M., & O’Brien, R. L. (2016) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-016-0403-0 · Cited by 15
Role of Adaptive Immune and Impacts of Risk Factors on Adaptive Immune in Alzheimer’s Disease: Are Immunotherapies Effective or Off-Target?
Shi, M., Chu, F., Tian, X., Aerqin, Q., Zhu, F., & Zhu, J. (2021) · The Neuroscientist · doi:10.1177/1073858420987224 · Cited by 14
Fighting fire with fire: The immune system might be key in our fight against Alzheimer’s disease
Dujardin, P., Vandenbroucke, R. E., & Hoecke, L. V. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.004 · Cited by 14
Anti‐NeuGcGM3 reactivity: a possible role of natural antibodies and B‐1 cells in tumor immunosurveillance
Rodríguez‐Zhurbenko, N., Rabade‐Chediak, M., Bedoya, D. M., Griñán, T., & Hernández, A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12827 · Cited by 14
Human Anti-Aβ IgGs Target Conformational Epitopes on Synthetic Dimer Assemblies and the AD Brain-Derived Peptide
Welzel, A. T., Williams, A. D., McWilliams‐Koeppen, H. P., Acero, L. F., Weber, A., Blinder, V., Mably, A. J., Bunk, S., Hermann, C., Farrell, M. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050317 · Cited by 13
Humoral ‘reactome’ profiles using peptide microarray chips
Valentini, D., Gaseitsiwe, S., & Maeurer, M. J. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.08.007 · Cited by 13
Immunosenescence of brain accelerates Alzheimer’s disease progression
Chen, H.-Y., Zhao, Y. G., & Xie, Y. (2022) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0021 · Cited by 12
Blood–Brain Barrier Transport of Alzheimer’s Amyloid β-Peptide
Nelson, A. R., Sagare, A. P., & Zloković, B. V. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00009-5 · Cited by 12
Blood and Cerebrospinal Fluid Autoantibody to Aβ Levels in Patients with Alzheimer’s Disease: a Meta-Analysis Study
Li, X., Li, X., Liu, Q., & Cheng, Y. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01528-5 · Cited by 13
Altered Blood Levels of Anti-Gal Antibodies in Alzheimer’s Disease: A New Clue to Pathogenesis?
Angiolillo, A., Gandaglia, A., Arcaro, A., Carpi, A., Gentile, F., Naso, F., & Costanzo, A. D. (2021) · Life · doi:10.3390/life11060538 · Cited by 12
The Forgotten Brother: The Innate-like B1 Cell in Multiple Sclerosis
Halperin, S. T., Hart, B. A. ‘., Luchicchi, A., & Schenk, G. J. (2022) · Biomedicines · doi:10.3390/biomedicines10030606 · Cited by 12
Corrigendum: T Cell Responses to Neural Autoantigens Are Similar in Alzheimer's Disease Patients and Age-Matched Healthy Controls
Dhanwani, R., Pham, J. W., Premlal, A. L. R., Frazier, A., Kumar, A., Pero, M. E., Bartolini, F., Dutra, J. R., Marder, K. S., Peters, B., et al. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.641809 · Cited by 11
β-Amyloids and Immune Responses Associated with Alzheimer’s Disease
Kolobova, E. A., Petrushanko, I. Y., Mitkevich, V. A., Makarov, A. А., & Grigorova, I. (2024) · Cells · doi:10.3390/cells13191624 · Cited by 10
Fishing for Biomarkers with Antigen Mimics
Lindström, T. M., & Robinson, W. H. (2011) · Cell · doi:10.1016/j.cell.2010.12.022 · Cited by 10
Self-citation
Nonhuman Amyloid Oligomer Epitope Reduces Alzheimer’s-Like Neuropathology in 3xTg-AD Transgenic Mice
Rasool, S., Martínez‐Coria, H., Milton, S. C. F., & Glabe, C. G. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8478-7 · Cited by 10
Designed Short Peptides that Form Amyloid‐Like Fibrils in Coassembly with Amyloid β‐Peptide (Aβ) Decrease the Toxicity of Aβ to Neuronal PC12 Cells
Suzuki, M. M., Takahashi, T., Sato, J., Mie, M., Kobatake, E., & Mihara, H. (2010) · ChemBioChem · doi:10.1002/cbic.201000181 · Cited by 10
Kinoids: A Family of Immunogens for Active Anticytokine Immunotherapy Applied to Autoimmune Diseases and Cancer
Bizzini, B., Drouet, B., Zagury, D., Abitbol, M. M., Burny, A., & Boissier, M. (2010) · Immunotherapy · doi:10.2217/imt.10.16 · Cited by 10
Rejecting the Alzheimer's disease vaccine development for the wrong reasons
Marciani, D. J. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.10.012 · Cited by 10
Solving the Amyloid Paradox: Unveiling the Complex Pathogenicity of Amyloid Fibrils
Sulatsky, M. I., Stepanenko, O. V., Stepanenko, O. V., & Sulatskaya, A. I. (2025) · Aggregate · doi:10.1002/agt2.70078 · Cited by 9
Human B-1 cells are important contributors to the naturally-occurring IgM pool against the tumor-associated ganglioside Neu5GcGM3
Rodríguez‐Zhurbenko, N., Quách, T. D., Rothstein, T. L., & Hernández, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1061651 · Cited by 9
Opportunities for Conformation-Selective Antibodies in Amyloid-Related Diseases
Westwood, M., & Lawson, A. D. G. (2015) · Antibodies · doi:10.3390/antib4030170 · Cited by 9
Lowered Serum Amyloid-β1-42 Autoantibodies in Individuals with Lifetime Depression
Maetzler, W., Langkamp, M., Lerche, S., Godau, J., Brockmann, K., Gaenslen, A., Huber, H., Wurster, I., Niebler, R., Eschweiler, G. W., et al. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120625 · Cited by 9
Alzheimers Disease: Review of Emerging Treatment Role for Intravenous Immunoglobulins
Kayed, R., Jackson, G. R., Estes, D. M., & Barrett, A. D. T. (2011) · Journal of Central Nervous System Disease · doi:10.4137/jcnsd.s5018 · Cited by 9
Animal Models of Alzheimer’s Disease: Utilization of Transgenic Alzheimer’s Disease Models in Studies of Amyloid Beta Clearance
Malm, T., Magga, J. M., & Koıstınaho, J. (2012) · Current Translational Geriatrics and Experimental Gerontology Reports · doi:10.1007/s13670-011-0004-z · Cited by 9
APOE Genotype Alters Immunoglobulin Subtypes in Knock-In Mice
Zhou, Y., Zhao, W., Al‐Muhtasib, N., & Rebeck, G. W. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142184 · Cited by 9
Quantitative determination of human IgA subclasses and their Fc‐glycosylation patterns in plasma by using a peptide analogue internal standard and ultra‐high‐performance liquid chromatography/triple quadrupole mass spectrometry
Chen, H., Shiao, C., Wu, M., Lin, Y., Chen, H.-H., Chang, W., Wu, K., Kao, C., & Tsai, I. (2019) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.8606 · Cited by 6
Deciphering the autoreactome: Massively parallelized methods for autoantibody detection in humans
Hörstke, N. V., & Vogl, T. J. (2025) · Journal of Immunological Methods · doi:10.1016/j.jim.2025.113876 · Cited by 5
Facing Alzheimer’s disease in the developing countries.
Marciani, D. J. (2017) · Revista de Neuro-Psiquiatría · doi:10.20453/rnp.v80i2.3091 · Cited by 5
Disease-specific adaptive immune biomarkers in Alzheimer's disease and related pathologies
Dorothée, G., Sarazin, M., & Aucouturier, P. (2013) · Revue Neurologique · doi:10.1016/j.neurol.2013.07.023 · Cited by 5
Construction of human Fab library and screening of a single-domain antibody of amyloid-beta 42 oligomers.
Yuan, Z., Du, M., Chen, Y., & Dou, F. (2013) · PubMed Central · doi:10.3969/j.issn.1673-5374.2013.33.004 · Cited by 6
A Quantitative View on Naturally Occurring Autoantibodies in Neurodegenerative Diseases
Dodel, R. C. (2018) · Journal of Neurology and Neuromedicine · doi:10.29245/2572.942x/2018/4.1189 · Cited by 5
Does Alzheimer disease exist in all primates? Alzheimer pathology in non-human primates and its pathophysiological implications (II)
Tolédano, A., Álvarez, M. I., López-Rodríguez, A. B., Toledano‐Díaz, A., & Fernández, C. I. (2014) · Neurología (English Edition) · doi:10.1016/j.nrleng.2011.05.006 · Cited by 5
Emerging Therapeutic Strategies in Alzheimer's Disease
Chiba, T. (2013) · InTech eBooks · doi:10.5772/55293 · Cited by 5
Immunotherapy Against N-Truncated Amyloid-β Oligomers
Bayer, T. A., & Wirths, O. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3560-4_3 · Cited by 4
Increase in Platelet Immunoglobulin in Alzheimer's Disease is Normalised Following Cholinesterase Inhibitor Treatment: Preliminary Results
Mukaetova‐Ladinska, E. B., Abdel‐All, Z., Andrade, J., McNally, R., James, P. W., Kalaria, R. N., & O'Brien, J. T. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120481 · Cited by 4
Biomarker Modelling of Early Molecular Changes in Alzheimer’s Disease
Paterson, R. W., Toombs, J., Slattery, C. F., Schott, J. M., & Zetterberg, H. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0069-9 · Cited by 5
Altered levels of circulating natural antibodies against VEGFR1-derived peptide in atherosclerosis
Wang, P., Liu, S., Wang, Z., Zhao, H., & Zhang, X. (2020) · Journal of International Medical Research · doi:10.1177/0300060520948750 · Cited by 4
Aggregation-dependent epitope sequence and modification fingerprints of anti-Aβ antibodiesPreprint
Talucci, I., Leske, T., Klafki, H., Hassan, M. M., Steiert, A., Morgado, B., Bothe, S., Werven, L. V., Liepold, T., Walter, J., et al. (2025) · eLife · doi:10.7554/elife.106156 · Cited by 4
Aggregation-dependent epitope sequence and modification fingerprints of anti-Aβ antibodies
Talucci, I., Leske, T., Klafki, H., Mehedi, H. M., Annik, S., Morgado, B., Bothe, S., Lars, V. W., Liepold, T., Walter, J., et al. (2026) · eLife · doi:10.7554/elife.106156.3 · Cited by 4
Memory Phenotype Tfh Cells Develop Without Overt Infection and Support Germinal Center Formation and B Cell Responses to Viral Infection
Symonds, A. L. J., Busharat, Z., Du, M., Miao, T., Li, S., Hou, X., & Wang, P. (2024) · European Journal of Immunology · doi:10.1002/eji.202451291 · Cited by 4
The Emerging Role of Immunoglobulins and Complement in the Stimulation of Neuronal Activity and Repair: Not as Simple as We Thought
Veremeyko, T., Barteneva, N. S., Vorobjev, I. A., & Ponomarev, E. D. (2024) · Biomolecules · doi:10.3390/biom14101323 · Cited by 3
Artificial intelligence and omics-based autoantibody profiling in dementia
Matsuda, K. M., Umeda‐Kameyama, Y., Iwadoh, K., Miyawaki, M., Yakabe, M., Ishii, M., Ogawa, S., Akishita, M., Sato, S., & Yoshizaki, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1537659 · Cited by 3
Activation of B-1 Cells
Rothstein, T. L., & Holodick, N. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-374279-7.09021-4 · Cited by 3
Elucidation of Amyloid-Beta’s Gambit in Oligomerization: Truncated Aβ fragments of residues Aβ1-23, Aβ1-24 and Aβ1-25 rapidly seed to form SDS-stable, LMW Aβ oligomers that impair synaptic plasticityPreprint
Gil, B., Rose, J. L., Demurtas, D., Mancini, G., Sordet‐Dessimoz, J., Sorrentino, V., Rudinskiy, N., Frosch, M. P., Hyman, B. T., Moniatte, M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.04.519021 · Cited by 3
Do human B-1 lymphocytes truly exist?
Martínez-Gutiérrez, M. I., Cañedo-Solares, I., Gómez-Chávez, F., Molina-López, L. M., Flores-Rabasa, R., Magdaleno-Villanueva, J. A., León-Pedroza, J. I., & Correa, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1810144 · Cited by 2
Intravenous immunoglobulin for the treatment of Alzheimer's disease: current evidence and considerations
Schindowski, K., Schindowski, C., & Zimmermann, J. (2014) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s51786 · Cited by 2
The Immunopathy of Alzheimer’s Disease: Innate or Adaptive?
Weaver, D. F. (2023) · Current Alzheimer Research · doi:10.2174/1567205020666230517103312 · Cited by 2
Epitope Sequence and Modification Fingerprints of Anti-Aβ AntibodiesPreprint
Talucci, I., Leske, T., Klafki, H., Hassan, M. M., Steiert, A., Morgado, B., Bothe, S., Werven, L. V., Liepold, T., Walter, J., et al. (2025) · eLife · doi:10.7554/elife.106156.1 · Cited by 2
The role of autoantibodies in Alzheimer's disease: Pathogenetic connections or epiphenomena?
Chatanaka, M. K., Prassas, I., Masters, C. L., & Diamandis, E. P. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70484 · Cited by 1
Asparaginase-like protein 1 and human endogenous retroviruses link immune and gene dysregulation in dementia
Simula, E. R., Ercoli, T., Ruiu, E., Fais, M., Noli, M., Solla, P., & Sechi, L. A. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1777560 · Cited by 1
Safety, tolerability and immunogenicity of vaccine ALZ-101 in patients with early Alzheimer’s disease: randomised, controlled trial
Lovró, Z., Sandberg, A., Zetterberg, H., Pierrou, S. E., Parkkola, R., Sjögren, N., Scheinin, M., & Rinne, J. O. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02082-9 · Cited by 2
Conformation-Dependent Antibodies as Tools for Characterization of Amyloid Protein Aggregates
Wu, J., & Breydo, L. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394431-3.00008-0 · Cited by 1
Les réponses immunitaires adaptatives contre le peptide amyloïde Aβ dans la maladie d’Alzheimer
Dorothée, G., & Aucouturier, P. (2011) · médecine/sciences · doi:10.1051/medsci/20112711008 · Cited by 3
Anti-Amyloid-β Immunotherapy: A Leading Novel Avenue for Alzheimer's Disease
Babbar, R., Sharma, P., Sharma, T., Madaan, P., Arora, S., & Badavath, V. N. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557522666220524090354 · Cited by 1
Epigenetic and non-epigenetic mechanisms in the accelerated cellular aging in late-onset Alzheimer’s disease
Rawat, K., & Garlapally, P. (2023) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2023.00040 · Cited by 1
The Diagnostic Potential of Circulating Autoantibodies to Amyloid-β in Alzheimer’s Disease
Xu, G.-Y., Liu, Y., Zeng, X., Chen, D., Zeng, G., Fan, D., Liu, Y.-H., & Wang, Y. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230252 · Cited by 1
The Importance of Vaccines in Preventing Impending Alzheimer’s Epidemic
Tripathi, S., Sharma, Y., & Kumar, D. (2025) · Reviews on Recent Clinical Trials · doi:10.2174/0115748871357356250325071712 · Cited by 1
Prophylactic and Therapeutic Applications of Catalytic Immunoglobulin Gene Delivery in a Mouse Model of Alzheimer’s Disease
Fukuchi, K., Yang, J., Kou, J., Song, M., Lalonde, R., Planque, S. A., & Paul, S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809813-4.00006-5 · Cited by 1
Contribution of the Commensal Microflora to the Immunological Homeostasis and the Importance of Immune-Related Drug Development for Clinical Applications
Beutgen, V. M., Schmelter, C., Pfeiffer, N., & Grus, F. H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168896 · Cited by 1
Artificial intelligence and omics-based autoantibody profiling highlights autoimmunity targeting ligand-receptor interaction in dementiaPreprint
Matsuda, K. M., Umeda‐Kameyama, Y., Iwadoh, K., Miyawaki, M., Yakabe, M., Ishii, M., Ogawa, S., Akishita, M., Sato, S., & Yoshizaki, A. (2024) · medRxiv · doi:10.1101/2024.09.20.24313547 · Cited by 1
Is there a role for B cells in Alzheimer's disease?
Charavner, E.-L., Fillatreau, S., & El Behi, M. (2026) · Cellular Immunology · doi:10.1016/j.cellimm.2026.105154
Do natural antibodies prevent Alzheimer disease?
Jones, N. K. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.125
SPECIFIC AMYLOID-BETA OLIGOMERS IN HUMAN CEREBROSPINAL FLUID
Handoko, M. (2012) · University of Minnesota Digital Conservancy (University of Minnesota)
Neurodegenerative Processes In Alzheimer‘s Disease: An Overview of Pathogenesis With Strategic Biomarker Potential
Rothenberg, K. G., Siedlak, S. L., Lee, H., Zhu, X., Perry, G. L., & Smith, M. A. (2011) · Future Neurology · doi:10.2217/fnl.10.81
Targeting cytotoxic species in amyloid diseases
Persson, M. (2012)
Protein adducts as measures of exposure in epidemiological research
Funk, W. E. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/1pq0-qj46
Amyloid beta 4-42 in Alzheimer’s disease: Target, Therapy, Mechanism
Antonios, G. (2016) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-5611
Alzheimer's disease: Toward the rational design of an effective vaccine. Enfermedad de Alzheimer: Hacia el diseño racional de una vacuna eficaz.
Marciani, D. J. (2015)
Development and characterization of cell models of tau aggregation
Cavallini, A. (2018) · UCL Discovery (University College London)
Biomarker Discovery for Alzheimer’s Disease Using NAPPA and In Vivo Crystallization in Baculovirus-Infected Insect Cells for Structural Biology
Tang, Y. (2020)
Distinct serum anti-Aβ antibody patterns in hemorrhagic and inflammatory cerebral amyloid angiopathy manifestationsPreprint
Chantran, Y., Capron, J., Doukhi, D., Felix, J., Féroul, M., Kruse, F., Chaigneau, T., Dorothée, G., Allou, T., Ayrignac, X., et al. (2020) · medRxiv · doi:10.1101/2020.10.07.20208330
Erratum to: Animal Models of Alzheimer’s Disease: Utilization of Transgenic Alzheimer’s Disease Models in Studies of Amyloid Beta Clearance
Malm, T., Magga, J. M., & Koıstınaho, J. (2012) · Current Translational Geriatrics and Experimental Gerontology Reports · doi:10.1007/s13670-012-0008-3
Studies on the Involvement of the Immune system in Alzheimer's disease
Marcello, A. (2010) · doi:10.53846/goediss-3277
Neuroimmunologie
Himmerich, H. (2011) · Springer eBooks · doi:10.1007/978-3-642-19844-1_42
Alteration of circulating natural antibodies against VEGFR1-derived peptide antigens in atherosclerosisPreprint
Wang, P., Liu, S., Wang, Z., Zhao, H., & Zhang, X. (2020) · doi:10.21203/rs.2.21125/v1
Changes in the public IgM repertoire and its idiotypic connectivity in Alzheimer's disease and frontotemporal dementia
Pashova, S., Petrov, P. V., Karachanak-Yankova, S., Belezhanska, D., Zhelev, Y., Mehrabian, S., Toncheva, D. I., Traykov, L., & Pashov, A. D. (2025) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2025.578775
Aggregation-Dependent Epitope Sequence and Modification Fingerprints of Anti-Aβ AntibodiesPreprint
Talucci, I., Leske, T., Klafki, H., Hassan, M., Steiert, A., Morgado, B., Bothe, S., Werven, L. V., Liepold, T., Walter, J., et al. (2025) · eLife · doi:10.7554/elife.106156.2
Plasma Autoantibodies Against Neurodegeneration-Related Antigens in Dementia and Elevated Chi3Li Autoantibodies in Mild Cognitive Impairment
Kocurova, G., Svabenska, Z., Klaschka, J., Bartoš, A., & Říčný, J. (2026) · Biomolecules · doi:10.3390/biom16040518
Contribution à l’étude des anticorps dirigés contre le peptide Aβ et de leur implication dans l’angiopathie amyloïde cérébrale
Chantran, Y. (2020) · theses.fr (ABES) · doi:10.70675/85da59a6z44afz49ecz8d9bz231a28465826
Interaction of therapeutic antibodies with heme : functional repercussions and prediction of developability issues
Kanyavuz, A. (2022) · doi:10.70675/45f8ab45zab05z478dzb41azaf4496ced5ac
Hunting for an Antigen: Humoral Immunity in Alzheimer’s Disease
Delgado, A. M., Greer, B. D., Maul, R. W., & Gearhart, P. J. (2026) · Cells · doi:10.3390/cells15131227

Authors: Britschgi, M., Olin, C. E., Johns, H. T., Takeda-Uchimura, Y., LeMieux, M. C., Rufibach, K., Rajadas, J., Zhang, H., Tomooka, B., Robinson, W. H., Clark, C. M., Fagan, A. M., Galasko, D. R., Holtzman, D. M., Jutel, M., Kaye, J. A., Lemere, C. A., Leszek, J., Li, G., Peskind, E. R., Quinn, J. F., Yesavage, J. A., Ghiso, J. A., & Wyss-Coray, T.
Affiliations: Stanford Medicine (US)
Stanford University (US)
Departments of aNeurology and Neurological Sciences and
University of Zurich (CH)
VA Palo Alto Health Care System (US)
University of Pennsylvania (US)
Washington University in St. Louis (US)
University of California San Diego (US)
Wroclaw Medical University (PL)
Oregon Health & Science University (US)
Brigham and Women's Hospital (US)
University of Washington (US)
NYU Langone Health (US)
ORCID: Britschgi, M.
Rufibach, K.
Rajadas, J.
Robinson, W. H.
Fagan, A. M.
Galasko, D. R.
Holtzman, D. M.
Jutel, M.
Kaye, J. A.
Lemere, C. A.
Leszek, J.
Peskind, E. R.
Quinn, J. F.
Yesavage, J. A.
Ghiso, J. A.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2009-07-21
Volume: 106
Issue: 29
Pages: 12145-12150
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.0904866106
PMC: PMC2715538
OpenAlex: W2132576841
Cited by: 201
References: 65
Citations by year: 2026: 8 · 2025: 12 · 2024: 8 · 2023: 11 · 2022: 16 · 2021: 9 · 2020: 15 · 2019: 7 · 2018: 5 · 2017: 4 · 2016: 16 · 2015: 12 · 2014: 10 · 2013: 12 · 2012: 20
FWCI: 12.41
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
Zurich Open Repository and Archive (University of Zurich)
Funders: National Institute on Aging (P01AG010491, AG10491, AG 08017, AG20603, R01AG020603, P30AG008017, R01AG030539, AG030539, P50AG005136)
National Institute of Neurological Disorders and Stroke (R01NS136122)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: Alzheimer's disease, natural antibodies, amyloid-beta, amyloid oligomers, neuroprotection, aging, cerebrospinal fluid, plasma IgG, pyroglutamic acid, ABRI, Adán, conformation-specific antibodies, vervet monkey, immunization, passive immunotherapy, peptide microarrays
MeSH terms: Aging, Alzheimer Disease, Animals, Antibodies, Dementia, Genes, Dominant, Immunoglobulin G, Immunization, Molecular Weight, Neurons, Peptides, Primates, Protein Processing, Post-Translational, Amyloid beta-Peptides, Disease Progression, Neuroprotective Agents, Cytoprotection, Protein Structure, Quaternary, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks